<DOC>
	<DOCNO>NCT02551419</DOCNO>
	<brief_summary>A six month , placebo-controlled , parallel group project MCI participant receive 30 g/day custom-made MCT-based ketogenic supplement match placebo . Uptake brain 's fuel - ketone ( 11C-AcAc ) glucose ( FDG ) - intervention assess PET ( position emission tomography ) imaging , well fMRI , diffusion MRI cognition .</brief_summary>
	<brief_title>Proof Mechanism New Ketogenic Supplement Using Dual Tracer PET ( Positron Emission Tomography )</brief_title>
	<detailed_description />
	<mesh_term>Cognition Disorders</mesh_term>
	<mesh_term>Mild Cognitive Impairment</mesh_term>
	<criteria>MoCA score ≥26/30 good physical autonomy diseases psychiatric disorder could interfere participation ; fast plasma glucose ≥6.0 mM ; substance abuse ; already supplement coconut oil MCT ; nut allergy ; visual hearing impairment impede comprehension ; nonEnglish/French speaking ; institutionalization ; intention move immediate area within 1 year ; participation another intervention trial</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>mild cognitive impairment</keyword>
	<keyword>ketone</keyword>
	<keyword>medium chain triglyceride</keyword>
	<keyword>Positron emission tomography</keyword>
	<keyword>magnetic resonance imaging</keyword>
	<keyword>cognition</keyword>
	<keyword>brain</keyword>
	<keyword>neuroimaging</keyword>
</DOC>